Cannabigerolic Acid (CBGA) inhibits the TRPM7 ion channel through its kinase domain

/by

In this study, we comprehensively investigated the most common major and minor cannabinoids to determine their potential efficacy on TRPM7 channel function. Here, we found that approximately half of the cannabinoids tested suppressed TRPM7 currents to some degree, with CBGA having the strongest inhibitory effect on TRPM7. We determined that the CBGA-mediated inhibition of TRPM7 requires a functional kinase domain , is sensitized by both intracellular Mg⋅ATP and free Mg2+, and reduced by increases in intracellular Ca2+. Finally, we demonstrate that CBGA inhibits native TRPM7 in B lymphocytes cell line.

Read more

Association between marijuana use and kidney stone: a cross-sectional study of NHANES 2009 to 2018

/by

The purpose of this investigation is to determine whether regular marijuana use is related to history of kidney stones in the US population. Data were obtained from the National Health and Nutrition Examination Survey (NHANES) from 2009 to 2018. Kidney stone and marijuana use data were collected from self-report questionnaires. Multivariate logistic regression and multiple sensitivity analyses were applied to examine the relationship between marijuana usage and kidney stones.

Read more

CBGA ameliorates inflammation and fibrosis in nephropathy

/by

Cannabidiol (CBD) is thought to have multiple biological effects, including the ability to attenuate inflammatory processes. Cannabigerols (CBGA and its decarboxylated CBG molecule) have pharmacological profiles similar to CBD. The endocannabinoid system has recently emerged to contribute to kidney disease, however, the therapeutic properties of cannabinoids in kidney disease remain largely unknown. In this study, we determined whether CBD and CBGA can attenuate kidney damage in an acute kidney disease model induced by the chemotherapeutic cisplatin. In addition, we evaluated the anti-fibrosis effects of these cannabinoids in a chronic kidney disease model induced by unilateral ureteral obstruction (UUO). We find that CBGA, but not CBD, protects the kidney from cisplatin-induced nephrotoxicity.

Read more

A Retrospective Cohort Study That Examined the Impact of Cannabis Consumption on Long-Term Kidney Outcomes

/by

Cannabis consumption for recreational and medical use is increasing worldwide. However, the long-term effects on kidney health and disease are largely unknown. Post hoc analysis of cannabis use as a risk factor for kidney disease was performed using data from the Assessment, Serial Evaluation, and Subsequent Sequelae of Acute Kidney Injury (ASSESS-AKI) study that enrolled hospitalized adults with and without acute kidney injury from four U.S. centers during 2009–2015. Associations between self-reported cannabis consumption and the categorical and continuous outcomes were determined using multivariable Cox regression and linear mixed models, respectively.

Read more

Cannabinoids in Urology. Which Benign Conditions Might They Be Appropriate to Treat: A Systematic Review

/by

Authors: Brian Robert Peter Birch, Charlie Taylor Published in Urology November 2020 Abstract There is growing evidence suggesting cannabinoids may provide suitable alternatives to conventional treatments in an increasing number…

Read more

Overexpression of cannabinoid receptor 1 promotes renal cell carcinoma progression

/by

Authors: Jianfeng Wang, Yunze Xu, Yun Zou, Liangsong Zhu, Baijun Dong, Jiwei Huang, Yonghui Chen, Wei Xue, Yiran Huang, Wen Kong & Jin Zhang Published in Tumor Biology October 2016 Abstract…

Read more

Marijuana and Cannabinoids in ESRD and Earlier Stages of CKD

/by

Authors: Joshua L. Rein, Christina M. Wyatt Published in American Journal of Kidney Diseases August 2017 Abstract Marijuana is the most commonly used recreational drug in the United States, and legal…

Read more

Cannabinoid-2 receptor limits inflammation, oxidative/nitrosative stress, and cell death in nephropathy

/by

Authors: Partha Mukhopadhyaya, Mohanraj Rajesha, Hao Pan, Vivek Patel, Bani Mukhopadhyaya, Sándor Bátkai, Bin Gao, György Haskóc, Pál Pachera Published in Journal of Pain and Symptom Management February 2010 Abstract Cisplatin…

Read more

Nephrologist Views Regarding Cannabinoid Use in Advanced Chronic Kidney Disease and Dialysis: A Survey

/by

Authors: David Collister, MD, PhD, Karthik Tennankore, MD, SM, Sara N. Davison, MD, MHSc, Ron Wald, MD, MPH, Christian Rabbat, MD, MSc, Michael Walsh, MD, PhD Published in Journal of…

Read more

Cannabinoid-2 receptor activation ameliorates hepatorenal syndrome

/by

Authors: Eszter Trojnar, Katalin Erdelyi,Csaba Matyas, Suxian Zhao, Janos Paloczi, Partha Mukhopadhyay, Zoltan V.Varga, Gyorgy Hasko, Pal Pacher Published in Free Radical Biology and Medicine May 2020 Abstract Study rationale: Hepatorenal…

Read more